Celgene Corporation, CELG is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Celgene Corporation, CELG has a market cap of 94675.17. Since its IPO date on the 3/26/1990, Celgene Corporation, CELG performance year to date is 1.98%. Today Celgene Corporation, CELG has gained -1.05%, with a current price of 120.84.
Ownership of the company is 0.20% for insider ownership while institutional ownership is 77.90%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 8.00%, with return on investment at 8.90%.
In terms of debt levels and profit levels, Celgene Corporation, CELG is seeing a long-term debt/equity of 2.44. While Total debt/equity is 2.53. With a profit margin of 19.70%, this is combined with a gross margin of 96.00%, and operating margin of 28.30%. Celgene Corporation ability to meet debt levels, with a current ratio of 3.6, while the quick ratio is 3.4.
For the last year Celgene Corporation, CELG has seen a EPS growth of -18.80%. A performance for the year of 11.59%. The 52-week high is -4.85%, and the 52-week low is 29.87%. The average volume for Celgene Corporation, CELG is 589763.
With a target price of 137.91, can Celgene Corporation, CELG reach this target? Looking at the value indicators of Celgene Corporation, CELG. Celgene Corporation has a P/E of 46.28 and a forward P/E of 17.32. Perhaps the more useful indicator than P/E, is PEG which has a value of 2.05. Celgene Corporation also has a P/S and a P/B of 8.76 and 16.78 respectively. For P/cash, Celgene Corporation has a value of 13.78, while it is 28 for P/free cash flow.
At the current price of 120.84, Celgene Corporation has a dividend yield of *TBA. We see a return on equity of 38.40%.
Looking more long-term Celgene Corporation, is projected to get an EPS growth for the next five years of 22.53%. In the short-term an EPS growth of 19.13% in the next year is forecasted. This is after a EPS growth of -18.80% for this year and for the last five years a 15.70% growth has been seen.